Akash Mishra, Anupam Jyoti, Krishna Aayush, Juhi Saxena, Kanika Sharma
{"title":"Harnessing Nanoparticles to Overcome Antimicrobial Resistance: Promises and Challenges.","authors":"Akash Mishra, Anupam Jyoti, Krishna Aayush, Juhi Saxena, Kanika Sharma","doi":"10.2174/0113816128326718240809091654","DOIUrl":null,"url":null,"abstract":"<p><p>The rise of antimicrobial resistance (AMR) has become a serious global health issue that kills millions of people each year globally. AMR developed in bacteria is difficult to treat and poses a challenge to clinicians. Bacteria develop resistance through a variety of processes, including biofilm growth, targeted area alterations, and therapeutic drug alteration, prolonging the period they remain within cells, where antibiotics are useless at therapeutic levels. This rise in resistance is linked to increased illness and death, highlighting the urgent need for effective solutions to combat this growing challenge. Nanoparticles (NPs) offer unique solutions for fighting AMR bacteria. Being smaller in size with a high surface area, enhancing interaction with bacteria makes the NPs strong antibacterial agents against various infections. In this review, we have discussed the epidemiology and mechanism of AMR development. Furthermore, the role of nanoparticles as antibacterial agents, and their role in drug delivery has been addressed. Additionally, the potential, challenges, toxicity, and future prospects of nanoparticles as antibacterial agents against AMR pathogens have been discussed. The research work discussed in this review links with Sustainable Development Goal 3 (SDG-3), which aims to ensure disease-free lives and promote well-being for all ages.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128326718240809091654","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
The rise of antimicrobial resistance (AMR) has become a serious global health issue that kills millions of people each year globally. AMR developed in bacteria is difficult to treat and poses a challenge to clinicians. Bacteria develop resistance through a variety of processes, including biofilm growth, targeted area alterations, and therapeutic drug alteration, prolonging the period they remain within cells, where antibiotics are useless at therapeutic levels. This rise in resistance is linked to increased illness and death, highlighting the urgent need for effective solutions to combat this growing challenge. Nanoparticles (NPs) offer unique solutions for fighting AMR bacteria. Being smaller in size with a high surface area, enhancing interaction with bacteria makes the NPs strong antibacterial agents against various infections. In this review, we have discussed the epidemiology and mechanism of AMR development. Furthermore, the role of nanoparticles as antibacterial agents, and their role in drug delivery has been addressed. Additionally, the potential, challenges, toxicity, and future prospects of nanoparticles as antibacterial agents against AMR pathogens have been discussed. The research work discussed in this review links with Sustainable Development Goal 3 (SDG-3), which aims to ensure disease-free lives and promote well-being for all ages.
抗菌药耐药性(AMR)的增加已成为一个严重的全球健康问题,每年导致全球数百万人死亡。细菌产生的 AMR 难以治疗,给临床医生带来了挑战。细菌通过各种过程产生耐药性,包括生物膜生长、靶区改变和治疗药物改变,从而延长了细菌在细胞内的存活时间,使抗生素在治疗水平上失去作用。抗药性的增加与疾病和死亡的增加有关,因此迫切需要有效的解决方案来应对这一日益严峻的挑战。纳米粒子(NPs)为抗击 AMR 细菌提供了独特的解决方案。纳米粒子体积小、比表面积大,能增强与细菌的相互作用,是抗击各种感染的强力抗菌剂。在这篇综述中,我们讨论了 AMR 的流行病学和发展机制。此外,还讨论了纳米粒子作为抗菌剂的作用及其在药物输送中的作用。此外,我们还讨论了纳米粒子作为抗菌剂对抗 AMR 病原体的潜力、挑战、毒性和未来前景。本综述中讨论的研究工作与可持续发展目标 3(SDG-3)相关联,该目标旨在确保无疾病生活并促进所有年龄段的人的福祉。
期刊介绍:
Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.